CU6 Share Price Performance
Recent CU6 News & Updates
No updates
Clarity Pharmaceuticals Ltd Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.13
- Gross Margin
- 100.00%
- Net Profit Margin
- -451.93%
- Debt/Equity Ratio
- 0%
Clarity Pharmaceuticals Ltd Competitors
About CU6
- Founded
- 2010
- Employees
- 50
- CEO
- WebsiteView website
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.
Australian Market Performance
- 7 Days: 0.2%
- 3 Months: 7.6%
- 1 Year: 8.9%
- Year to Date: 5.7%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 8.9% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading